Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced that its board of directors has initiated an exploration of strategic alternatives. As part of this process, the board will consider a wide range of options for the company including, among other things, a potential merger, spin-off, sale, or other strategic transaction for one or more of its key business units or assets.
“As our company continues to expand into complementary revenue streams, we believe the time is right to investigate a range of strategic alternatives with the intent to pursue profitable growth and maximize shareholder value,” said Jeffrey Ervin, IMAC’s Chief Executive Officer. “We have developed a range of regenerative and organic applications for spinal health and wellness and expect to publish record revenue in our 2nd quarter filing as evidence of this progress. We simply see a disconnect between asset values we have developed and the value our assets may have to partners.”
IMAC Holdings was originally formed in 2015 to expand on the footprint of the IMAC Regeneration Center, which first opened in Kentucky in 2000. The company has since added additional avenues of business and now has three areas of focus:
There can be no assurance that this process will result in the company pursuing a particular transaction or other strategic outcome. IMAC has not set a timetable for completion of this process, and it does not intend to disclose further developments unless and until it determines that further disclosure is appropriate or necessary.
IMAC has retained Joseph Gunnar & Co. LLC as its exclusive financial advisor to assist in the review process.